Patents by Inventor Geoffrey Allan Pietersz

Geoffrey Allan Pietersz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENHANCED VIRAL DELIVERY FORMULATION
    Publication number: 20210038660
    Abstract: The present invention relates generally to recombinant adenoviral pharmaceutical formulations. More particularly, the present invention relates to SiO2-gel-based controlled release recombinant adenoviral pharmaceutical formulations.
    Type: Application
    Filed: July 22, 2020
    Publication date: February 11, 2021
    Applicant: Ascend Biopharmaceuticals Ltd
    Inventors: Clement Leong, Geoffrey Allan Pietersz
  • Flu vaccine admixture of mannan and flu antigen
    Patent number: 8182821
    Abstract: The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: May 22, 2012
    Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health Ltd.
    Inventors: Geoffrey Allan Pietersz, Sandra Elizabeth Esparon, Owen Proudfoot
  • Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS
    Publication number: 20110144170
    Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 16, 2011
    Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
  • Fc receptor modulating compounds and compositions
    Patent number: 7910770
    Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: March 22, 2011
    Assignee: Trillium Therapeutics Inc.
    Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
  • VACCINE
    Publication number: 20110033493
    Abstract: The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament.
    Type: Application
    Filed: June 11, 2010
    Publication date: February 10, 2011
    Applicants: AUSTIN RESEARCH INSTITUTE, THE, MELBOURNE, UNIVERSITY OF, THE
    Inventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Christina Cheers, John Stambas
  • FLU VACCINE ADMIXTURE OF MANNAN AND FLU ANTIGEN
    Publication number: 20100008951
    Abstract: The present invention relates to a vaccine composition comprising a carbohydrate polymer comprising mannose and flu antigen(s) (e.g. whole inactivated influenza virus) in admixture, and a method of immunising a subject comprising the step of administering the vaccine composition to a subject.
    Type: Application
    Filed: October 2, 2007
    Publication date: January 14, 2010
    Applicant: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED
    Inventors: Geoffrey Allan Pietersz, Sandra Elizabeth Esparon, Owen Proudfoot
  • CANCER VACCINE COMPRISING A MUCIN 1 (MUC1) T CELL EPITOPE-DERIVED PEPTIDE
    Publication number: 20090317414
    Abstract: A cancer vaccine, and a composition for the ex vivo priming of dendritic cells, is disclosed which comprises a MUC1 T cell epitope-derived peptide or peptide analogue capable of provoking a cytotoxic T cell immune response. Particular MUC1 T cell epitope-derived peptides disclosed include TTAPPVHGL, STAPPVHGL, STAPPAHGL, TTAPPAHGV and SAPDTYPAL.
    Type: Application
    Filed: July 25, 2007
    Publication date: December 24, 2009
    Applicant: 4G VACCINES PTY LTD
    Inventors: Geoffrey Allan Pietersz, Vasso Apostolopoulos, Ian Farquhar Campbell McKenzie
  • Fc Receptor Modulating Compounds and Compositions
    Publication number: 20080146632
    Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl zing substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.
    Type: Application
    Filed: February 1, 2008
    Publication date: June 19, 2008
    Applicant: TRILLIUM THERAPEUTICS, INC.
    Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
  • Fc receptor modulating compounds and compositions
    Patent number: 7332631
    Abstract: The present invention provides compounds capable of binding to an Fc receptor and modulating Fc receptor activity comprising a core lipophilic group in the form of an Aryl ring substituted with a group rich in p-electrons. The invention further provides for a method of treating an autoimmune disease involving Fc receptor activity using such compounds. A method for obtaining a compound which modulates Fc receptor activity is also provided, the method comprising: (a) providing or designing compounds having structural characteristics to fit in the groove of the Fc?RIIa structure; and (b) screening the compounds for modulating activity on the Fc receptor.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: February 19, 2008
    Assignee: Trillium Therapeutics Inc.
    Inventors: Mark Phillip Hogarth, Geoffrey Allan Pietersz, Gerard Peter Moloney
  • Vaccine
    Publication number: 20040043032
    Abstract: The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament.
    Type: Application
    Filed: May 12, 2003
    Publication date: March 4, 2004
    Inventors: lan Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Christina Cheers, John Stambas
  • Immunogobulin conjugates
    Patent number: 5798097
    Abstract: Immunoglobulin conjugates, comprising idarubicin (Ida) conjugated to a monoclonal antibody or fragment thereof comprising at least one of the antigen binding sites of the antigen, are useful for treating a human or other animal suffering from a cancer or for depleting a subset of T lymphocytes from a population of cells.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: August 25, 1998
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Ian Farquhar Campbell McKenzie, Geoffrey Allan Pietersz, Mark John Smyth